References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. https://doi.org/10.3322/caac.21492
- Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat 2020;52:335-350. https://doi.org/10.4143/crt.2020.206
- Schistosomes, liver flukes and Helicobacter pylori. IARC working group on the evaluation of carcinogenic risks to humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241.
- Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 2014;348:g3174. https://doi.org/10.1136/bmj.g3174
- Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori Therapy for the prevention of metachronous gastric cancer. N Engl J Med 2018;378:1085-1095. https://doi.org/10.1056/NEJMoa1708423
- Choi IJ, Kim CG, Lee JY, et al. Family history of gastric cancer and helicobacter pylori treatment. N Engl J Med 2020;382:427-436. https://doi.org/10.1056/NEJMoa1909666
- Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-194. https://doi.org/10.1001/jama.291.2.187
- Chen HN, Wang Z, Li X, Zhou ZG. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a metaanalysis. Gastric Cancer 2016;19:166-175. https://doi.org/10.1007/s10120-015-0462-7
- Wu XD, Zeng K, Xue FQ, Chen JH, Chen YQ. Statins are associated with reduced risk of gastric cancer: a meta-analysis. Eur J Clin Pharmacol 2013;69:1855-1860. https://doi.org/10.1007/s00228-013-1547-z
- Bosetti C, Santucci C, Gallus S, Martinetti M, La Vecchia C. Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019. Ann Oncol 2020;31:558-568. https://doi.org/10.1016/j.annonc.2020.02.012
- Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PloS ONE 2013;8:e71583. https://doi.org/10.1371/journal.pone.0071583
- Americal Diabetes Association. 8. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care 2017;40:S64-S74. https://doi.org/10.2337/dc17-S011
- Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia 2017;60:1577-1585. https://doi.org/10.1007/s00125-017-4342-z
- Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-1305. https://doi.org/10.1136/bmj.38415.708634.f7
- Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a populationbased cohort study. Am J Gastroenterol 2012;107:46-52. https://doi.org/10.1038/ajg.2011.384
- Ruiter R, Visser LE, van Herk-Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 2012;35:119-124. https://doi.org/10.2337/dc11-0857
- Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-1625. https://doi.org/10.2337/dc08-2175
- van Staa TP, Patel D, Gallagher AM, de Bruin ML. Glucoselowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 2012;55:654-665. https://doi.org/10.1007/s00125-011-2390-3
- Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC cancer 2011;11:20. https://doi.org/10.1186/1471-2407-11-20
- Kim YI, Kim SY, Cho SJ, et al. Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort study. Aliment Pharmacol Thera 2014;39:854-863. https://doi.org/10.1111/apt.12660
- Valent F. Diabetes mellitus and cancer of the digestive organs: An Italian population-based cohort study. J Diabetes Complications 2015;29:1056-1061. https://doi.org/10.1016/j.jdiacomp.2015.07.017
- Tseng CH. Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus. Aging 2016;8:1636-1649. https://doi.org/10.18632/aging.101019
- Steward WP, Brown K. Cancer chemoprevention: a rapidly evolving field. Br J Cancer 2013;109:1-7. https://doi.org/10.1038/bjc.2013.280
- Morse MA, Stoner GD. Cancer chemoprevention: principles and prospects. Carcinogenesis 1993;14:1737-1746. https://doi.org/10.1093/carcin/14.9.1737
- Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012;35:731-737. https://doi.org/10.2337/dc11-1299
- Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006:CD002967.
- Daugan M, Dufay Wojcicki A, d'Hayer B, Boudy V. Metformin: An anti-diabetic drug to fight cancer. Pharmacol Res 2016;113:675-685. https://doi.org/10.1016/j.phrs.2016.10.006
- Vijg J, Campisi J. Puzzles, promises and a cure for ageing. Nature 2008;454:1065-1071. https://doi.org/10.1038/nature07216
- Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-10273. https://doi.org/10.1158/0008-5472.CAN-06-1500
- Pietrocola F, Kroemer G. Metformin: a metabolic modulator. Oncotarget 2017;8:9017-9020. https://doi.org/10.18632/oncotarget.14794
- Del Barco S, Vazquez-Martin A, Cufi S, et al. Metformin: multi-faceted protection against cancer. Oncotarget 2011;2:896-917. https://doi.org/10.18632/oncotarget.387
- Jalving M, Gietema JA, Lefrandt JD, et al. Metformin: taking away the candy for cancer? Eur J Cancer 2010;46:2369-2380. https://doi.org/10.1016/j.ejca.2010.06.012
- Ersoy C, Kiyici S, Budak F, et al. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res Clin Pract 2008;81:56-60. https://doi.org/10.1016/j.diabres.2008.02.006
- Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576-3586. https://doi.org/10.1038/sj.onc.1211024
- Kato K, Gong J, Iwama H, et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther 2012;11:549-560. https://doi.org/10.1158/1535-7163.MCT-11-0594
- Yu G, Fang W, Xia T, et al. Metformin potentiates rapamycin and cisplatin in gastric cancer in mice. Oncotarget 2015;6:12748-12762. https://doi.org/10.18632/oncotarget.3327
- Zhuang S, Jian Y, Sun Y. Metformin inhibits N-Methyl-NNitrosourea induced gastric tumorigenesis in db/db mice. Exp Clin Endocrinol Diabetes 2017;125:392-399. https://doi.org/10.1055/s-0043-100118
- Valaee S, Yaghoobi MM, Shamsara M. Metformin inhibits gastric cancer cells metastatic traits through suppression of epithelial-mesenchymal transition in a glucose-independent manner. PloS ONE 2017;12:e0174486. https://doi.org/10.1371/journal.pone.0174486
- Kim J, Hyun HJ, Choi EA, Kim Y, Bae YJ, Kang HT. Metformin use reduced the risk of stomach cancer in diabetic patients in Korea: an analysis of Korean NHIS-HEALS database. Gastric Cancer 2020;23:1075-1083. https://doi.org/10.1007/s10120-020-01085-1